Northwest Biotherapeutics NWBO

OTC: NWBO | ISIN: US66737P6007   27/06/2025
0,240 USD (-4,00%)
(-4,00%)   27/06/2025

3 juli 2024 · Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities · Persbericht

17 juni 2024 · Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property · Persbericht

21 maart 2024 · Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors · Persbericht

6 februari 2024 · Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification · Persbericht

21 december 2023 · Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma · Persbericht

13 oktober 2023 · Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application · Persbericht

12 september 2023 · Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board · Persbericht

29 augustus 2023 · Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application · Persbericht

21 maart 2023 · Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility · Persbericht

12 maart 2023 · Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB · Persbericht

6 januari 2023 · Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023 · Persbericht

17 november 2022 · Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma · Persbericht

23 augustus 2022 · Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA · Persbericht

6 juli 2022 · Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility · Persbericht

6 juni 2022 · Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program · Persbericht

10 mei 2022 · Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well · Persbericht

4 mei 2022 · Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences · Persbericht

17 februari 2022 · Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility · Persbericht

29 november 2021 · Northwest Biotherapeutics Announces $15 Million Financing · Persbericht

28 oktober 2021 · Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility · Persbericht

Mijn selecties